Predicting mortality after hormonal therapy for postsurgical or postradiologic PSA failure
Carol Lovegrove
This article has no abstract so we have provided the first paragraph of the full text.
Around 30% of patients with localized prostate cancer who undergo radical prostatectomy or external-beam radiation therapy show PSA failure within 10 years and median survival in these patients is related to PSA doubling time. PSA doubling time prior to the initiation of primary androgen-suppression therapy (AST) has also been associated with prostate-cancer-specific mortality (PCSM), as has posthormonal PSA nadir. Although it has been shown that patients who do not achieve a post-AST nadir below 0.2 ng/ml following primary treatment have an increased risk of PCSM, it is not known whether this also applies in cases of secondary AST given for PSA failure after surgery or radiation therapy.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.